{"id":55120,"date":"2026-01-22T11:00:02","date_gmt":"2026-01-22T03:00:02","guid":{"rendered":"https:\/\/flcube.com\/?p=55120"},"modified":"2026-01-22T11:00:03","modified_gmt":"2026-01-22T03:00:03","slug":"abbotts-tactiflex-duo-wins-ce-mark-for-atrial-fibrillation-treatment-in-europe","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55120","title":{"rendered":"Abbott\u2019s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe"},"content":{"rendered":"\n<p><strong>Abbott<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABT:NYSE\">NYSE:\u202fABT<\/a>) announced it has received <strong>CE Mark approval in Europe<\/strong> for the <strong>TactiFlex Duo Ablation Catheter, Sensor Enabled<\/strong> to treat patients with <strong>atrial fibrillation (AFib)<\/strong>. The first successful commercial cases using TactiFlex Duo in the European Union were completed this week, marking the entry of the <strong>dual\u2011energy pulsed field ablation (PFA) catheter<\/strong> into clinical practice.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Abbott (NYSE:\u202fABT)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TactiFlex Duo Ablation Catheter, Sensor Enabled<\/td><\/tr><tr><td><strong>Certification<\/strong><\/td><td>CE Mark (European Union)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Treatment of atrial fibrillation (AFib)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Pulsed field ablation (PFA) delivering RF + PFA energy<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>20\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Study Support<\/strong><\/td><td>FOCALFLEX CE Mark study<\/td><\/tr><tr><td><strong>First Commercial Cases<\/strong><\/td><td>Completed this week in EU<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-device-profile-amp-mechanism\">Device Profile &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual\u2011Energy Platform:<\/strong> Combines <strong>radiofrequency (RF) energy<\/strong> and <strong>pulsed field ablation (PFA)<\/strong> to deliver <strong>tailored therapy lesions<\/strong><\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong><\/li>\n\n\n\n<li><strong>PFA energy<\/strong> creates <strong>irreversible electroporation<\/strong> of cardiac tissue, selectively ablating myocardium while sparing surrounding structures<\/li>\n\n\n\n<li><strong>RF energy<\/strong> provides <strong>thermal ablation<\/strong> for backup or hybrid lesions<\/li>\n\n\n\n<li><strong>Sensor Integration:<\/strong> <strong>Real\u2011time contact force and impedance sensing<\/strong> enables <strong>precise lesion delivery<\/strong> and <strong>reduces procedure time<\/strong><\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> Offers <strong>flexibility<\/strong> to choose energy modality based on patient anatomy and physician preference<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-competitive-landscape\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>EU AFib Ablation Market<\/th><th>Global AFib Market<\/th><\/tr><\/thead><tbody><tr><td><strong>AFib Prevalence (2026E)<\/strong><\/td><td>6.5\u202fmillion<\/td><td>33\u202fmillion<\/td><\/tr><tr><td><strong>Ablation Procedures (2026E)<\/strong><\/td><td>180,000<\/td><td>850,000<\/td><\/tr><tr><td><strong>PFA Penetration<\/strong><\/td><td>25%<\/td><td>18%<\/td><\/tr><tr><td><strong>Market Value (2030E)<\/strong><\/td><td>\u20ac2.4\u202fbillion<\/td><td>$8.5\u202fbillion<\/td><\/tr><tr><td><strong>Abbott Market Share<\/strong><\/td><td>12%<\/td><td>8%<\/td><\/tr><tr><td><strong>TactiFlex Duo Peak Revenue<\/strong><\/td><td>\u20ac290\u202fmillion<\/td><td>$680\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Boston Scientific<\/strong> \u2013 FARAPULSE PFA system (market leader, 60% share)<\/li>\n\n\n\n<li><strong>Medtronic<\/strong> \u2013 PulseSelect PFA system (FDA approved, EU rollout)<\/li>\n\n\n\n<li><strong>Johnson &amp; Johnson<\/strong> \u2013 VARIPULSE PFA system (late\u2011stage)<\/li>\n\n\n\n<li><strong>TactiFlex Duo<\/strong> \u2013 <strong>First dual\u2011energy system<\/strong> (RF + PFA); <strong>differentiated flexibility<\/strong> vs. pure PFA competitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Validation:<\/strong> <strong>FOCALFLEX study<\/strong> demonstrated <strong>clinically meaningful safety and effectiveness<\/strong> in AFib patients, supporting <strong>broad EU reimbursement<\/strong><\/li>\n\n\n\n<li><strong>Commercial Launch:<\/strong> <strong>Abbott\u2019s 400\u2011person EP sales force<\/strong> in Europe will promote TactiFlex Duo; <strong>targeting 200 high\u2011volume AFib centers<\/strong> by Q4\u202f2026<\/li>\n\n\n\n<li><strong>Next\u2011Generation Pipeline:<\/strong> Platform being adapted for <strong>ventricular tachycardia ablation<\/strong> and <strong>pulmonary vein isolation<\/strong> enhancements<\/li>\n\n\n\n<li><strong>US Pathway:<\/strong> <strong>FDA IDE application<\/strong> planned for <strong>Q3\u202f2026<\/strong>, leveraging EU data for <strong>accelerated approval<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, market penetration, and revenue forecasts for TactiFlex Duo. Actual results may differ due to competitive responses, reimbursement negotiations, and clinical adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abbott (NYSE:\u202fABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[503,69,870,15],"class_list":["post-55120","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-abbott","tag-cvd","tag-nyse-abt","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Abbott\u2019s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Abbott (NYSE:\u202fABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with atrial fibrillation (AFib). The first successful commercial cases using TactiFlex Duo in the European Union were completed this week, marking the entry of the dual\u2011energy pulsed field ablation (PFA) catheter into clinical practice.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55120\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbott\u2019s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe\" \/>\n<meta property=\"og:description\" content=\"Abbott (NYSE:\u202fABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with atrial fibrillation (AFib). The first successful commercial cases using TactiFlex Duo in the European Union were completed this week, marking the entry of the dual\u2011energy pulsed field ablation (PFA) catheter into clinical practice.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55120\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T03:00:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T03:00:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55120#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55120\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Abbott\u2019s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe\",\"datePublished\":\"2026-01-22T03:00:02+00:00\",\"dateModified\":\"2026-01-22T03:00:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55120\"},\"wordCount\":389,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Abbott\",\"CVD\",\"NYSE: ABT\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55120#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55120\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55120\",\"name\":\"Abbott\u2019s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T03:00:02+00:00\",\"dateModified\":\"2026-01-22T03:00:03+00:00\",\"description\":\"Abbott (NYSE:\u202fABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with atrial fibrillation (AFib). The first successful commercial cases using TactiFlex Duo in the European Union were completed this week, marking the entry of the dual\u2011energy pulsed field ablation (PFA) catheter into clinical practice.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55120#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55120\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55120#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbott\u2019s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abbott\u2019s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe - Insight, China&#039;s Pharmaceutical Industry","description":"Abbott (NYSE:\u202fABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with atrial fibrillation (AFib). The first successful commercial cases using TactiFlex Duo in the European Union were completed this week, marking the entry of the dual\u2011energy pulsed field ablation (PFA) catheter into clinical practice.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55120","og_locale":"en_US","og_type":"article","og_title":"Abbott\u2019s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe","og_description":"Abbott (NYSE:\u202fABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with atrial fibrillation (AFib). The first successful commercial cases using TactiFlex Duo in the European Union were completed this week, marking the entry of the dual\u2011energy pulsed field ablation (PFA) catheter into clinical practice.","og_url":"https:\/\/flcube.com\/?p=55120","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T03:00:02+00:00","article_modified_time":"2026-01-22T03:00:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55120#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55120"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Abbott\u2019s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe","datePublished":"2026-01-22T03:00:02+00:00","dateModified":"2026-01-22T03:00:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55120"},"wordCount":389,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Abbott","CVD","NYSE: ABT","Product approvals"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55120#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55120","url":"https:\/\/flcube.com\/?p=55120","name":"Abbott\u2019s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T03:00:02+00:00","dateModified":"2026-01-22T03:00:03+00:00","description":"Abbott (NYSE:\u202fABT) announced it has received CE Mark approval in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with atrial fibrillation (AFib). The first successful commercial cases using TactiFlex Duo in the European Union were completed this week, marking the entry of the dual\u2011energy pulsed field ablation (PFA) catheter into clinical practice.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55120#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55120"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55120#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Abbott\u2019s TactiFlex Duo Wins CE Mark for Atrial Fibrillation Treatment in Europe"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55120"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55120\/revisions"}],"predecessor-version":[{"id":55121,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55120\/revisions\/55121"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}